Sucampo Pharma Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUCAMPO PHARMA LLC, and what generic alternatives to SUCAMPO PHARMA LLC drugs are available?
SUCAMPO PHARMA LLC has two approved drugs.
There are five US patents protecting SUCAMPO PHARMA LLC drugs.
There are seventy patent family members on SUCAMPO PHARMA LLC drugs in nineteen countries and five supplementary protection certificates in five countries.
Summary for Sucampo Pharma Llc
International Patents: | 70 |
US Patents: | 5 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Sucampo Pharma Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | AB | RX | Yes | No | 8,748,481 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | AB | RX | Yes | Yes | 8,748,481 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | AB | RX | Yes | No | 7,795,312 | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sucampo Pharma Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | 8,114,890 | ⤷ Try a Trial |
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | 8,097,653 | ⤷ Try a Trial |
Sucampo Pharma Llc | RESCULA | unoprostone isopropyl | SOLUTION/DROPS;OPHTHALMIC | 021214-001 | Aug 3, 2000 | 6,770,675 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SUCAMPO PHARMA LLC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Ophthalmic Solution | 0.15% | ➤ Subscribe | 2014-05-12 |
➤ Subscribe | Capsules | 8 mcg and 24 mcg | ➤ Subscribe | 2012-08-20 |
International Patents for Sucampo Pharma Llc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20120045051 | ⤷ Try a Trial |
South Korea | 20070048221 | ⤷ Try a Trial |
China | 101048163 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sucampo Pharma Llc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2298314 | 92826 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LUBIPROSTONE, INCLUANT LES SELS PHARMACEUTIQUEMENT ACCEPTABLES, LES ESTERS OU LES AMIDES DE LA LUBIPROSTONE. FIRST REGISTRATION: 20120910 |
0289349 | C300135 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: UNOPROSTONEZUUR, DESGEWENST IN DE VORM VAN EEN ESTER OF EEN ZOUT; NATL REGISTRATION NO/DATE: RVG 28628 20030708; FIRST REGISTRATION: FR 359 911-5 AND 359 912-1 20020917 |
1315485 | 132016000025193 | Italy | ⤷ Try a Trial | PRODUCT NAME: LUBIPROSTONE O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(AMITIZA); AUTHORISATION NUMBER(S) AND DATE(S): PL 21341/0003, 20120910;043833019-021, 20150526 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.